



Dexilant® (dexlansoprazole) – First-time authorized brand alternative

- On December 17, 2021, TWi Pharmaceuticals launched an authorized brand alternative of Takeda's [Dexilant \(dexlansoprazole\)](#) delayed-release capsules.
- Dexilant is approved in patients 12 years of age and older for the healing of erosive esophagitis; maintenance of healed erosive esophagitis and relief of heartburn; and treatment of symptomatic non-erosive gastroesophageal reflux disease.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.